204 related articles for article (PubMed ID: 32454504)
1. Anti-VEGF Therapy Reduces Inflammation in Diabetic Macular Edema.
Imazeki M; Noma H; Yasuda K; Motohashi R; Goto H; Shimura M
Ophthalmic Res; 2021; 64(1):43-49. PubMed ID: 32454504
[TBL] [Abstract][Full Text] [Related]
2. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
[TBL] [Abstract][Full Text] [Related]
3. Effects of ranibizumab on growth factors and mediators of inflammation in the aqueous humor of patients with diabetic macular edema.
Utsumi T; Noma H; Yasuda K; Goto H; Shimura M
Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2597-2603. PubMed ID: 33772356
[TBL] [Abstract][Full Text] [Related]
4. Functional-morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab.
Noma H; Mimura T; Yasuda K; Shimura M
Br J Ophthalmol; 2017 Feb; 101(2):180-185. PubMed ID: 27073207
[TBL] [Abstract][Full Text] [Related]
5. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
Felfeli T; Juncal VR; Hillier RJ; Mak MYK; Wong DT; Berger AR; Kohly RP; Kertes PJ; Eng KT; Boyd SR; Altomare F; Giavedoni LR; Muni RH
Am J Ophthalmol; 2019 Oct; 206():176-183. PubMed ID: 30959004
[TBL] [Abstract][Full Text] [Related]
6. Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema.
Shimura M; Yasuda K; Motohashi R; Kotake O; Noma H
Br J Ophthalmol; 2017 Nov; 101(11):1518-1523. PubMed ID: 28270488
[TBL] [Abstract][Full Text] [Related]
7. Correlation between anterior chamber flare changes and diabetic macular edema after intravitreal injection of ranibizumab and aflibercept.
Shiraya T; Kure K; Araki F; Kato S; Kaiya T
Jpn J Ophthalmol; 2020 May; 64(3):250-256. PubMed ID: 32108920
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion.
Mashima A; Noma H; Yasuda K; Goto H; Shimura M
J Inflamm (Lond); 2019; 16():9. PubMed ID: 31139023
[TBL] [Abstract][Full Text] [Related]
9. Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema.
Noma H; Yasuda K; Shimura M
Eur J Ophthalmol; 2021 Jan; 31(1):204-210. PubMed ID: 31690095
[TBL] [Abstract][Full Text] [Related]
10. Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema.
Podkowinski D; Orlowski-Wimmer E; Zlabinger G; Pollreisz A; Mursch-Edlmayr AS; Mariacher S; Ring M; Bolz M
Acta Ophthalmol; 2020 Jun; 98(4):e407-e415. PubMed ID: 31736269
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab Alters Levels of Intraocular Soluble Cytokine Receptors in Patients with Diabetic Macular Edema.
Coughlin BA; Guha-Niyogi P; Sikorskii A; Glazer LC; Mohr S
Curr Eye Res; 2020 Apr; 45(4):509-520. PubMed ID: 31488015
[No Abstract] [Full Text] [Related]
12. Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema.
Shiraya T; Kato S; Araki F; Ueta T; Miyaji T; Yamaguchi T
PLoS One; 2017; 12(3):e0174340. PubMed ID: 28346545
[TBL] [Abstract][Full Text] [Related]
13. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema.
Eriş E; Perente I; Vural E; Vural A; Seymen Z; Celebi ARC; Erdogan G; Ozkaya A; Artunay O
Int Ophthalmol; 2019 Jul; 39(7):1575-1580. PubMed ID: 29943100
[TBL] [Abstract][Full Text] [Related]
15. The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.
Hong IH; Choi W; Han JR
Jpn J Ophthalmol; 2020 Mar; 64(2):196-202. PubMed ID: 31900869
[TBL] [Abstract][Full Text] [Related]
16. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of Inflammatory Factors in Aqueous Humor during Ranibizumab or Aflibercept Treatment for Age-Related Macular Degeneration.
Motohashi R; Noma H; Yasuda K; Kotake O; Goto H; Shimura M
Ophthalmic Res; 2017; 58(4):209-216. PubMed ID: 28796997
[TBL] [Abstract][Full Text] [Related]
18. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
[TBL] [Abstract][Full Text] [Related]
19. Aqueous Humor Levels of Soluble Vascular Endothelial Growth Factor Receptor and Inflammatory Factors in Diabetic Macular Edema.
Noma H; Mimura T; Yasuda K; Motohashi R; Kotake O; Shimura M
Ophthalmologica; 2017; 238(1-2):81-88. PubMed ID: 28564655
[TBL] [Abstract][Full Text] [Related]
20. The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema.
Lim SW; Bandala-Sanchez E; Kolic M; Rogers SL; McAuley AK; Lim LL; Wickremasinghe SS
Invest Ophthalmol Vis Sci; 2018 Nov; 59(13):5382-5390. PubMed ID: 30452591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
